4-碘甲基四氢吡喃 | 101691-94-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 4-碘甲基四氢吡喃
• 英文名称: 4-(iodomethyl)tetrahydro-2H-pyran
• 英文别名: 4-iodomethyl-tetrahydro-pyran；4-iodomethyl-tetrahydropyrane；4-(iodomethyl)oxane
• CAS: 101691-94-5
• 化学式: C₆H₁₁IO
• mdl: MFCD06410724
• 分子量: 226.057
• InChiKey: MQLFSPBSNWUXSO-UHFFFAOYSA-N

物化性质

• 沸点：
  229.1±13.0 °C(Predicted)
• 密度：
  1.645±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险类别码：
  R34
• 海关编码：
  2932999099
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P280,P301+P310+P330+P331,P303+P361+P353+P310,P304+P340+P310,P305+P351+P338+P310,P363,P405,P501
• 危险品运输编号：
  3265
• 危险性描述：
  H314
• 储存条件：
  2-8°C

SDS

Name:	4-(Iodomethyl)tetrahydro-2H-pyran Material Safety Data Sheet
Synonym:	None Known
CAS:	101691-94-5

Section 1 - Chemical Product MSDS Name:4-(Iodomethyl)tetrahydro-2H-pyran Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
101691-94-5	4-(Iodomethyl)tetrahydro-2h-pyran	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 101691-94-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Pale Yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H11IO
Molecular Weight: 226.06

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat.
Incompatibilities with Other Materials:
Acid chlorides, strong acids, strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, iodine, iodide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 101691-94-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Iodomethyl)tetrahydro-2h-pyran - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 101691-94-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 101691-94-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 101691-94-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-碘甲基四氢吡喃 在 吡啶 、 N-甲基吡咯烷酮 、 氯化亚砜 、 lithium hydroxide monohydrate 、 双氧水 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 水 、 甲苯 为溶剂， 反应 31.5h， 生成 (R)-2-(4-(环丙基磺酰基)苯基)-n-(吡嗪-2-基)-3-(四氢-2H-吡喃-4-基)丙酰胺
  参考文献：
  名称：

  葡糖激酶激活剂通过酮的不对称化可扩展合成非外消旋的α-芳基丙酸

  摘要：

  描述了合成手性羧酸（R）-2作为葡萄糖激酶激活剂（R）-1的关键中间体的方法研究和开发。在α-碳上构型的立体中心是合成（R）-2的关键点。所提出的方法利用由（R）-泛内酯作为手性助剂从相应的外消旋羧酸Rac -2原位生成的乙烯酮的脱对称化，然后将所得的酯水解。该关键步骤已成功放大到20 kg，这表明该合成方法与先前报道的通过对映选择性氢化的方法相当。

  DOI：

  10.1021/op400354g
• 作为产物：
  描述：

  (4-(羟基甲基)-四氢-2H-吡喃-4-基)甲烷磺酸盐 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 5.75h， 生成 4-碘甲基四氢吡喃
  参考文献：
  名称：

  葡糖激酶激活剂通过酮的不对称化可扩展合成非外消旋的α-芳基丙酸

  摘要：

  描述了合成手性羧酸（R）-2作为葡萄糖激酶激活剂（R）-1的关键中间体的方法研究和开发。在α-碳上构型的立体中心是合成（R）-2的关键点。所提出的方法利用由（R）-泛内酯作为手性助剂从相应的外消旋羧酸Rac -2原位生成的乙烯酮的脱对称化，然后将所得的酯水解。该关键步骤已成功放大到20 kg，这表明该合成方法与先前报道的通过对映选择性氢化的方法相当。

  DOI：

  10.1021/op400354g
• 作为试剂：
  描述：

  1-溴-4-(乙基磺酰基)苯 、 丙二酸二乙酯 、 Tripotassium;phosphate 、 sodium hydroxide 、 盐酸 在 醋酸钯 、 2-(二叔丁基膦)联苯 氩 、 氯化铵 、 乙酸乙酯 、 水 、 Brine 、 magnesium sulfate 、 silica gel 、 正己烷 、 N,N-二甲基甲酰胺 、 氮气 、 sodium;hydride 、 ice 、 4-碘甲基四氢吡喃 、 ethyl acetate n-hexane 作用下， 以 1,4-二氧六环 、 甲醇 、 四氢呋喃 为溶剂， 反应 18.25h， 以to give the title compound (1.33 g, yield 67%) as colorless crystals的产率得到2-(4-ethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid
  参考文献：
  名称：

  NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND

  摘要：

  本发明提供一种由公式(I)表示的化合物，其中每个符号如规范中所定义，或其盐。本发明的化合物具有葡萄糖激酶活性，并可用作药物，例如预防或治疗糖尿病、肥胖症等疾病的药剂，等等。

  公开号：

  US20100130446A1

文献信息

• [EN] SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] COMPOSÉS DE SULFONYLE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2013123444A1

  公开（公告）日：2013-08-22

  The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的磺酰基化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
  申请人：Ryono Denis E.

  公开号：US20080009465A1

  公开（公告）日：2008-01-10

  Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R 4 is —(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g , —(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g , —(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10 ), or —(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10 ); R 5 and R 6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

  提供了磷酸酯和磷酸酯激活剂，因此在治疗糖尿病和相关疾病方面非常有用，并具有以下结构： 其中 是杂环芳基环； R 4 为—(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 )、—(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g 、—(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g 、—(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10) 或—(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10) ； R 5 和R 6 分别选择自H、烷基和卤素； Y为R 7 (CH 2 ) s 或不存在；以及 X、n、Z、m、R 4 、R 5 、R 6 、R 7 和s如本文所定义；或其药用盐。 还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Florjancic S. Alan

  公开号：US20080058335A1

  公开（公告）日：2008-03-06

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , and L 1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1a , R 2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1 ，R 2 ，R 3 和L 1 在规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1a ，R 2a 和(Rx)n如规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
  作者：Hefeng Zhang、Xia Peng、Yang Dai、Jingwei Shao、Yinchun Ji、Yiming Sun、Bo Liu、Xu Cheng、Jing Ai、Wenhu Duan

  DOI：10.1021/acs.jmedchem.0c02093

  日期：2021.4.8

  therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and

  受体酪氨酸激酶 Axl 在促进癌症进展、转移和耐药性中发挥重要作用，并已被确定为抗癌治疗的有希望的靶点。我们从低微摩尔效力化合物9开始，使用分子建模辅助结构优化来发现化合物13c ，这是一种高效且可口服生物利用的 Axl 抑制剂。选择性分析表明， 13c可以抑制众所周知的致癌激酶 Met，其抑制 Axl 超家族激酶的效力相同。化合物13c显着抑制细胞Axl和Met信号传导，抑制Axl和Met驱动的细胞增殖，并抑制Gas6/Axl介导的癌细胞迁移或侵袭。此外， 13c在 Axl 驱动和 Met 驱动的肿瘤异种移植模型中表现出显着的抗肿瘤功效，在耐受良好的剂量下导致肿瘤停滞或消退。所有这些有利的数据使13c成为癌症治疗的有前途的候选药物。
• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2015120049A1

  公开（公告）日：2015-08-13

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开了作为成纤维细胞生长因子抑制剂（FGFR）的化合物，因此可用于治疗可以通过抑制FGFR治疗的疾病。还公开了含有此类化合物的药物组合物以及制备此类化合物的过程。